The main RAPS website will offline for several minutes at 5 PM on 22 October 2021 due to scheduled maintenance.
We apologize for any inconvenience during this time.

  • Senator Looks to Spur Development of Medicines Through 'Prize Fund'

    • 15 May 2012
    A Senate hearing being held by Senator Bernie Sanders (I-VT) seeks to advance legislation that would create a prize fund for companies to create new medicines and vaccines, partially replacing the current market-exclusivity model of product development. Sanders' legislation, S.1137: The Medical Innovation Prize Fund Act , was introduced in May 2011, but has thus far eluded much notice. In remarks on the Senate floor on 15 May, Sanders said he did not expect the bill...
  • House Goes After Pharmaceutical Companies, Seeking Info on PPACA Negotiations

    • 08 May 2012
    An investigation by the US House Energy and Commerce Committee that began in January 2012 continues to escalate, with members of the committee directly targeting pharmaceutical companies in an attempt to discover what went on between the Obama administration and the pharmaceutical industry during negotiations on the Patient Protection and Affordable Care Act in 2010, reports Bloomberg . Members of the House Energy and Commerce Committee oversee the healthcare sector, ...
  • Biosimilars Guidelines Attract Attention, Criticism

    As Genetic Engineering & Biotechnology News reported in mid-April, the US Food and Drug Administration's (FDA) draft biosimilar regulations attracted mostly negative comments . Now some companies are adding further commentary to the pile-and they're bringing up points of substantial friction with FDA. Pharmaceutical manufacturer Amgen told FDA regulators that "requiring the maintenance of biosimilarity over time would inhibit manufacturing and quality improvem...
  • PLoS: Pressures on Doha Declaration Signatories Preventing Overuse of Compulsory Licenses

    • 12 January 2012
    A recent study in the Public Library of Science's (PLoS) Medicine journal provides a review of the Doha Declaration , and finds that the issuance of compulsory licenses (CLs) dropped significantly after 2006, and that upper-middle-income countries (UMICs) face barriers to utilizing CL's excessively. Compulsory licenses are used by countries to override patents when the country deems that a health crisis warrants such action. When the Doha Declaration was first sig...